Leadless Pacemakers Global Market Report 2024

The leadless pacemakers market size has grown rapidly in recent years. It will grow from $0.51 billion in 2023 to $0.58 billion in 2024 at a compound annual growth rate (CAGR) of 15.2%. The growth during the historic period can be attributed to several factors, including enhanced imaging and navigation systems, an increased focus on minimally invasive procedures, the demand for improved quality of life, advancements in biocompatible materials, and the rising incidence of cardiovascular diseases.

The leadless pacemakers market size is expected to see rapid growth in the next few years. It will grow to $1.04 billion in 2028 at a compound annual growth rate (CAGR) of 15.5%. In the forecast period, growth can be attributed to expanding clinical indications, an aging population, a growing focus on patient safety and outcomes, increasing emphasis on sustainability, and rising public awareness and education. Major trends during this period include technological advancements and innovation, integration with wearable and digital health technologies, longer battery life and durability, patient-centric design and customization, and increased collaboration and partnerships within the industry.

The growth of the leadless pacemaker market is expected to be fueled by the increasing prevalence of heart disease in the future. Heart diseases encompass a range of conditions affecting the heart's structure or function, leading to issues such as impaired blood flow, abnormal heart rhythms, or other cardiovascular complications. The rise in heart diseases is attributed to factors such as population growth and aging, lifestyle choices, stress, physical inactivity, challenges within the healthcare system, as well as genetic and environmental factors. Leadless pacemakers offer significant benefits in managing specific heart diseases by providing effective pacing while reducing the risk of complications associated with traditional leads and offering a less invasive implantation procedure. For example, in February 2024, the World Health Organization (WHO) projected over 35 million new cases of heart disease by 2050, marking a 77% increase from the estimated 20 million cases in 2022. Thus, the increasing prevalence of heart disease is a driving force behind the growth of the leadless pacemaker market.

Leading companies in the leadless pacemaker market are focusing on developing innovative products, such as dual-chamber leadless pacemakers, to cater to a wider range of cardiac conditions and provide patients with more personalized treatment options. A dual-chamber leadless pacemaker is a cardiac pacing device designed to regulate heart rhythms by delivering electrical impulses to the right atrium and ventricle without traditional pacing leads. For instance, in February 2022, Abbott Laboratories, a US-based medical devices and healthcare company, launched the AveirTM DR, a dual-chamber pacemaker that offers synchronized, beat-by-beat pacing of the right atrium and ventricle. The Aveir DR system utilizes proprietary i2iTM communication technology to enable beat-to-beat synchronous pacing between the atrium and ventricle, delivering true Dual-chamber rate-modulated (DDDR) pacing for continuous atrioventricular (AV) synchrony. This innovative leadless pacemaker system meets the critical need for dual-chamber pacing in patients requiring pacing in both heart chambers.

In August 2022, Medtronic, an Ireland-based medical device company, completed the acquisition of Affera Inc. for $925 million. This strategic move aims to expand Medtronic's cardiac ablation offerings and venture into the cardiac mapping and navigation market, leveraging Affera's technologies to deliver innovative therapies, address the increasing demand for arrhythmia treatment, and provide a comprehensive portfolio of safe and effective solutions for cardiac arrhythmias. Affera is a US-based medical device developer specializing in heart rhythm disorder treatments.

Major companies operating in the leadless pacemakers market are Abbott Laboratories, Medtronic Plc, Boston Scientific Corporation, Terumo Corporation, St. Jude Medical Inc., Lepu Medical Technology Co. Ltd., BIOTRONIK SE & Co. KG, LivaNova PLC, MicroPort Scientific Corporation, Oscor Inc., Sorin Group S.p.A., EBR Systems Inc., Vitatron Holding B.V., SORIN S.p.A, MEDICO S.p.A., Imricor Medical Systems Inc., Osypka Medical GmbH, Shree Pacetronix Ltd., CathRx Ltd., Cairdac.

North America was the largest region in the leadless pacemakers market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leadless pacemakers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the leadless pacemakers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Leadless pacemakers are a type of cardiac pacing device that delivers electrical stimulation to the heart without traditional leads (wires). These self-contained devices reduce the risk of lead-related complications such as infection, breakage, and displacement.

The primary types of leadless pacemakers include micra transcatheter pacing systems and others. The micra transcatheter pacing system (TPS) is specifically designed to provide pacing therapy for patients with bradycardia, a condition characterized by a slow or irregular heartbeat. These devices come in single-chamber and dual-chamber configurations and are utilized in various healthcare settings such as hospitals, specialty clinics, and others.

The leadless pacemakers market research report is one of a series of new reports that provides leadless pacemakers market statistics, including leadless pacemaker industry global market size, regional shares, competitors with a leadless pacemakers market share, detailed leadless pacemakers market segments, market trends, and opportunities, and any further data you may need to thrive in the leadless pacemaker industry. This leadless pacemakers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The leadless pacemakers market consists of sales of single-chamber leadless pacemakers, nanostim leadless pacemakers, dual-chamber leadless pacemakers, wireless cardiac resynchronization therapy (CRT) systems, and MRI-compatible leadless pacemakers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.